Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$18.82 USD
+0.51 (2.79%)
Updated May 31, 2024 04:00 PM ET
After-Market: $18.85 +0.03 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Akero Therapeutics, Inc. [AKRO]
Reports for Purchase
Showing records 81 - 100 ( 105 total )
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NASH Weekly: 2020 Is Packed With Clinical Data Readouts in NASH
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NASH Weekly: GLP-1 Data in 2Q20 Is Likely to Be Underwhelming
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Yas'' Weekly Recap of Our Key Notes
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Expert Call Recap for 2019 in NASH and Liver Disease
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Should You Attend AASLD in Boston? Use Our Day-By-Day Calendar to Figure It Out
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Our Doc Call with Dr. Arun Sanyal
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Let''s Dive Into FGF21 Biology With Dr. Arun Sanyal on Sept. 18 at 11am ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - September is the Key Month for NASH: Join Our Three Doc Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Join Our Doc Call Series on Drug Pricing
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
What Does It Take to Lift the Low NASH Sentiment?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y